FRANKLIN LAKES, N.J., Feb. 6, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.080 billion for the first fiscal quarter ended December 31, 2017. This represents an increase of 5.4 percent from the prior-year period, or 3.7 percent on a currency-neutral basis, and includes an estimated 110 basis point adverse impact from the previously disclosed change in the U.S. dispensing business model.

"We are proud of our performance in our final stand-alone quarter, as we continued to deliver solid, consistent results," said Vincent A. Forlenza, Chairman and CEO. "We look forward to the future with confidence as we welcome C.R. Bard to BD. Together, through our combined capabilities and the impact we can have on our customers and their patients, we have a tremendous opportunity to advance the world of health."

First Quarter Fiscal 2018 Operating Results
As reported, diluted earnings per share for the first quarter were $(0.76), compared with $2.58 in the prior-year period. This represents a decrease of 129.5 percent and is primarily due to restructuring, transaction and financing costs associated with acquisitions and additional tax expense relating to new U.S. tax legislation, as well as a litigation reserve reversal in the prior-year period following a favorable appellate antitrust ruling. Adjusted diluted earnings per share were $2.48, compared with $2.33 in the prior-year period. This represents an increase in adjusted diluted earnings per share of 6.4 percent, or 3.9 percent on a currency-neutral basis.

Segment Results
In the BD Medical segment, as reported, worldwide revenues for the quarter of $2.035 billion increased 3.6 percent from the prior-year period, or 1.9 percent on a currency-neutral basis, which includes an estimated 170 basis point impact from the change in the U.S. dispensing business model. The segment's results reflect strong performance in the Medication and Procedural Solutions unit and solid results in the Diabetes Care and Pharmaceutical Systems units. Performance in the Medication Management Solutions unit reflects the adverse impact of the change in the U.S. dispensing business model as well as a tough comparison due to the timing of capital placements in the prior-year period.

In the BD Life Sciences segment, as reported, worldwide revenues for the quarter were $1.045 billion, an increase of 9.1 percent over the prior-year period, or 7.3 percent on a currency-neutral basis. Revenue growth reflects strong performance across the segment. BD Life Sciences' growth was aided by flu-related revenues in the Diagnostic Systems unit as a result of an earlier start to the flu season in comparison to the prior year.

Business Affairs Homepage